miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
11
2018
accepted:
11
02
2020
entrez:
27
2
2020
pubmed:
27
2
2020
medline:
12
6
2020
Statut:
epublish
Résumé
MicroRNAs (miRNAs) inhibit protein function by silencing the translation of target mRNAs. However, in primary central nervous system lymphoma (PCNSL), the expression and functions of miRNAs are inadequately known. Here, we examined the expression of 847 miRNAs in 40 PCNSL patients with a microarray and investigated for the miRNA predictors associated with cancer immunity-related genes such as T helper cell type 1/2 (Th-1/Th-2) and regulatory T cell (T-reg) status, and stimulatory and inhibitory checkpoint genes, for prognosis prediction in PCNSL. The aim of this study is to find promising prognosis markers based on the miRNA expression in PCNSL. We detected 334 miRNAs related to 66 cancer immunity-related genes in the microarray profiling. Variable importance measured by the random survival forest analysis and Cox proportional hazards regression model elucidated that 11 miRNAs successfully constitute the survival formulae dividing the Kaplan-Meier curve of the respective PCNSL subgroups. On the other hand, univariate analysis shortlisted 23 miRNAs for overall survival times, with four miRNAs clearly dividing the survival curves-miR-101/548b/554/1202. These miRNAs regulated Th-1/Th-2 status, T-reg cell status, and immune checkpoints. The miRNAs were also associated with gene ontology terms as Ras/MAP-kinase, ubiquitin ligase, PRC2 and acetylation, CDK, and phosphorylation, and several diseases including acquired immunodeficiency syndrome, glioma, and those related to blood and hippocampus with statistical significance. In conclusion, the results demonstrated that the four miRNAs comprising miR-101/548b/554/1202 associated with cancer immunity can be a useful prognostic marker in PCNSL and would help us understand target pathways for PCNSL treatments.
Identifiants
pubmed: 32101576
doi: 10.1371/journal.pone.0229577
pii: PONE-D-18-33807
pmc: PMC7043771
doi:
Substances chimiques
Biomarkers, Tumor
0
MIRN101 microRNA, human
0
MIRN1202 microRNA, human
0
MIRN548 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0229577Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Neuropathol. 2014 Jan-Feb;33(1):42-9
pubmed: 24359606
Neuro Oncol. 2011 Oct;13(10):1090-8
pubmed: 21803762
J Pharmacol Exp Ther. 2018 Jan;364(1):1-12
pubmed: 29054858
Hepatology. 2016 Jul;64(1):245-60
pubmed: 26990797
Hepatol Res. 2014 Aug;44(8):837-45
pubmed: 23819517
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Biomed Pharmacother. 2017 Dec;96:1246-1252
pubmed: 29217161
Anticancer Res. 2017 Oct;37(10):5655-5666
pubmed: 28982883
Urol J. 2019 Jun 17;16(3):267-273
pubmed: 30318571
Ann Hematol. 2012 Apr;91(4):553-9
pubmed: 21987025
Oncotarget. 2018 Apr 10;9(27):19065-19078
pubmed: 29721184
Exp Ther Med. 2019 Sep;18(3):2332-2340
pubmed: 31452716
Curr Biol. 2001 Oct 2;11(19):R772-5
pubmed: 11591334
Adv Exp Med Biol. 2015;889:23-40
pubmed: 26658994
J Cell Physiol. 2018 Aug;233(8):5642-5654
pubmed: 29154447
Cancer Manag Res. 2019 Apr 05;11:2739-2746
pubmed: 31040714
Front Mol Neurosci. 2013 Nov 26;6:39
pubmed: 24324397
Mol Neurobiol. 2015;51(3):1452-61
pubmed: 25081587
Lasers Med Sci. 2019 Sep 5;:
pubmed: 31485783
Cancer Manag Res. 2019 Jun 25;11:5821-5834
pubmed: 31417317
Lancet. 2012 May 26;379(9830):1984-96
pubmed: 22510398
PLoS One. 2019 Jan 7;14(1):e0210400
pubmed: 30615673
Blood. 2018 Aug 16;132(7):681-688
pubmed: 29986908
Leuk Res. 2018 May 21;70:45-48
pubmed: 29807272
Int J Mol Sci. 2015 Dec 07;16(12):29103-19
pubmed: 26690130
PLoS One. 2017 Nov 13;12(11):e0187722
pubmed: 29131834
Clin Cancer Res. 2012 Oct 15;18(20):5672-81
pubmed: 22908096
Eur J Cancer. 2015 Feb;51(3):382-90
pubmed: 25534293
Blood Cancer J. 2017 Dec 15;7(12):654
pubmed: 29242506
Cancer Sci. 2018 Nov;109(11):3543-3553
pubmed: 30220099
Blood. 2017 Jun 8;129(23):3071-3073
pubmed: 28356247
Tumour Biol. 2017 Apr;39(4):1010428317697565
pubmed: 28443461
J Clin Exp Hematop. 2017 Jul 5;57(1):21-25
pubmed: 28496056
Oncotarget. 2017 Aug 14;8(50):87317-87328
pubmed: 29152083
Cell. 1999 Oct 15;99(2):123-32
pubmed: 10535731
Nat Rev Clin Oncol. 2016 Jan;13(1):25-40
pubmed: 26525683
Neoplasma. 2018 Nov 15;65(6):881-887
pubmed: 29940757
J Cell Physiol. 2012 Mar;227(3):1235-41
pubmed: 21688267
Clin Cancer Res. 2009 Oct 15;15(20):6446-53
pubmed: 19808874
Nat Med. 2014 Jul;20(7):764-8
pubmed: 24908571
J Clin Exp Hematop. 2018;58(2):95-101
pubmed: 29998979
Br J Haematol. 2008 Sep;142(5):732-44
pubmed: 18537969
Oncotarget. 2017 Sep 15;8(49):86020-86030
pubmed: 29156774
Neuroreport. 2016 Dec 7;27(17):1266-1273
pubmed: 27682888
PLoS One. 2019 May 10;14(5):e0216825
pubmed: 31075138
CNS Neurosci Ther. 2015 Jan;21(1):40-51
pubmed: 25230316
J Neurooncol. 2014 Apr;117(2):261-8
pubmed: 24488444
J Neurooncol. 2018 May;137(3):463-468
pubmed: 29327175
Oncotarget. 2018 Jun 8;9(44):27471-27486
pubmed: 29937999
Biomed Pharmacother. 2015 Oct;75:111-6
pubmed: 26297544
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Oncol Rep. 2017 Jun;37(6):3493-3501
pubmed: 28440476